Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Rubinstein

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Journal of the National Cancer Institute|January 26, 2023
COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS)Ana F Best, Melissa Bowman, Jessica Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignanciesShivaani Kummar, Larry Anderson, Kimberly Hill, et al.
Cell Cycle (Georgetown, Tex.)|November 22, 2011
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agentDiana Nguyen, Maria Zajac-Kaye, Larry Rubinstein, et al.
Clinical Pharmacology and Therapeutics|March 31, 2019
A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer VaccinesAkihiro Hirakawa, Kazuki Sudo, Kan Yonemori, et al.
Cancer Medicine|August 3, 2017
Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agentBeverly A Teicher, Thomas Silvers, Michael Selby, et al.
Investigational New Drugs|February 1, 2015
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancerKhanh Do, Giovanna Speranza, Rachel Bishop, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2010
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activityRobert J Kinders, Melinda Hollingshead, Scott Lawrence, et al.
Cancer Research|April 28, 2017
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic ActivitySusan L Holbeck, Richard Camalier, James A Crowell, et al.
Cancer Biology & Therapy|October 14, 2009
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomasSherry X Yang, Shivaani Kummar, Seth M Steinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2010
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cellsLihua H Wang, Thomas D Pfister, Ralph E Parchment, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|January 26, 2023
COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS)Ana F Best, Melissa Bowman, Jessica Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignanciesShivaani Kummar, Larry Anderson, Kimberly Hill, et al.
Cell Cycle (Georgetown, Tex.)|November 22, 2011
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agentDiana Nguyen, Maria Zajac-Kaye, Larry Rubinstein, et al.
Clinical Pharmacology and Therapeutics|March 31, 2019
A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer VaccinesAkihiro Hirakawa, Kazuki Sudo, Kan Yonemori, et al.
Cancer Medicine|August 3, 2017
Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agentBeverly A Teicher, Thomas Silvers, Michael Selby, et al.
Investigational New Drugs|February 1, 2015
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancerKhanh Do, Giovanna Speranza, Rachel Bishop, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2010
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activityRobert J Kinders, Melinda Hollingshead, Scott Lawrence, et al.
Cancer Research|April 28, 2017
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic ActivitySusan L Holbeck, Richard Camalier, James A Crowell, et al.
Cancer Biology & Therapy|October 14, 2009
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomasSherry X Yang, Shivaani Kummar, Seth M Steinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2010
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cellsLihua H Wang, Thomas D Pfister, Ralph E Parchment, et al.
Pageof 6